Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Low-dose ethinylestradiol/levonorgestrel.

Toni M Dando1, Monique P Curran

  • 1Adis International Limited, Auckland, New Zealand.

Drugs
|November 4, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Decitabine: a review of its use in older patients with acute myeloid leukaemia.

Drugs & aging·2013
Same author

Tadalafil: in the treatment of signs and symptoms of benign prostatic hyperplasia with or without erectile dysfunction.

Drugs & aging·2012
Same author

Transdermal granisetron: a guide to its use in preventing nausea and vomiting induced by chemotherapy.

CNS drugs·2012
Same author

Live attenuated influenza vaccine (Fluenz™): a guide to its use in the prevention of seasonal influenza in children in the EU.

Paediatric drugs·2012
Same author

Crizotinib: in locally advanced or metastatic non-small cell lung cancer.

Drugs·2011
Same author

Canakinumab: in patients with cryopyrin-associated periodic syndromes.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2011
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Low-dose ethinylestradiol/levonorgestrel 20 microg/100 microg is an effective combined oral contraceptive. This birth control method demonstrated a Pearl Index of 0.88 in a 3-year trial, showing high contraceptive efficacy.

Area of Science:

  • Reproductive Health
  • Pharmacology
  • Contraception

Background:

  • Combined oral contraceptives (COCs) are widely used for pregnancy prevention.
  • Low-dose formulations aim to balance efficacy with reduced side effects.
  • Ethinylestradiol/levonorgestrel is a common COC formulation.

Purpose of the Study:

  • To evaluate the contraceptive efficacy and safety of low-dose ethinylestradiol/levonorgestrel 20 microg/100 microg.
  • To assess cycle control and adverse events associated with this COC.
  • To compare its performance with other low-dose COCs.

Main Methods:

  • A 3-year open-label trial involving 1708 women and 26,554 cycles.
  • A 6-cycle comparative trial with 463 women and other low-dose COCs.

Related Experiment Videos

  • Data collection on pregnancies, adverse events, and cycle control.
  • Main Results:

    • Pearl Index of 0.88 and a 3-year cumulative pregnancy rate of 1.9%.
    • Contraceptive efficacy was comparable to other ethinylestradiol-based COCs.
    • Most common adverse events leading to discontinuation were headache and metrorrhagia (2%).
    • Generally good cycle control observed, with intermenstrual bleeding decreasing over time.

    Conclusions:

    • Ethinylestradiol/levonorgestrel 20 microg/100 microg offers reliable contraception.
    • The formulation is well-tolerated, with manageable adverse events.
    • It provides effective pregnancy prevention and good cycle control for users.